We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
-3.9%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.47B
AUM Growth
-$289M
Cap. Flow
-$262M
Cap. Flow %
-10.6%
Top 10 Hldgs %
61.17%
Holding
110
New
16
Increased
30
Reduced
10
Closed
25

Top Buys

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$15.8M
2
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$14.7M
3
INCY icon
Incyte
INCY
+$14.3M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$11.2M
5
TEX icon
Terex
TEX
+$6.1M

Top Sells

Rank Stock Value
1
FURX
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
+$78.4M
2
AMGN icon
Amgen
AMGN
+$17.4M
3
DG icon
Dollar General
DG
+$13.9M
4
MJN
Mead Johnson Nutrition Company
MJN
+$12.5M
5
BRFS
BRF SA
BRFS
+$10.1M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 25.19%
2 Healthcare 24.42%
3 Financials 1.12%
4 Industrials 0.54%
5 Technology 0.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GILD icon
26
CALL
Gilead Sciences
GILD
$166B
$20.7M 0.84%
250,000
– –
YUM icon
27
CALL
Yum! Brands
YUM
$42B
$20.3M 0.82%
347,750
-486,850
-58% -$27.1M
ALNY icon
28
Alnylam Pharmaceuticals
ALNY
$38.6B
$19M 0.77%
300,000
+95,000
+46% +$5.65M
IMGN
29
DELISTED
Immunogen Inc
IMGN
$17.8M 0.72%
1,500,000
+200,000
+15% +$2.51M
NKTR icon
30
Nektar Therapeutics
NKTR
$2.31B
$17.3M 0.7%
90,000
+3,333
+4% +$589K
APTV icon
31
CALL
Aptiv
APTV
$12.4B
$17.2M 0.69%
250,000
– –
CL icon
32
CALL
Colgate-Palmolive
CL
$74.2B
$17M 0.69%
250,000
– –
ONIT
33
CALL
Onity Group
ONIT
$339M
$16.7M 0.67%
30,000
-6,667
-18% -$3.63M
AMZN icon
34
Amazon
AMZN
$2.45T
$16.2M 0.66%
+1,000,000
New +$15.8M
QCOM icon
35
CALL
Qualcomm
QCOM
$169B
$15.8M 0.64%
200,000
-350,000
-64% -$27.8M
IONS icon
36
Ionis Pharmaceuticals
IONS
$9.12B
$15.7M 0.63%
455,000
+355,000
+355% +$11.2M
ACOR
37
DELISTED
Acorda Therapeutics
ACOR
$14.3M 0.58%
3,542
+625
+21% +$2.55M
C icon
38
Citigroup
C
$216B
$14.1M 0.57%
300,000
– –
ARRY
39
DELISTED
Array Biopharma Inc
ARRY
$13.7M 0.55%
3,000,000
– –
PCYC
40
CALL
DELISTED
PHARMACYCLICS INC
PCYC
$13.5M 0.54%
150,000
+60,000
+67% +$5.63M
VMC icon
41
CALL
Vulcan Materials
VMC
$37.4B
$12.8M 0.52%
+200,000
New +$12.7M
GM icon
42
General Motors
GM
$81.8B
$12.7M 0.51%
350,000
– –
LLY icon
43
CALL
Eli Lilly
LLY
$1.09T
$12.4M 0.5%
200,000
– –
BRFS
44
CALL
DELISTED
BRF SA
BRFS
$12.2M 0.49%
500,000
-1,000,000
-67% -$22.6M
AVNR
45
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$11.3M 0.46%
2,000,000
+1,100,000
+122% +$5.07M
FURX
46
CALL
DELISTED
FURIEX PHARMACEUTICALS INC COM STK (DE)
FURX
$10.6M 0.43%
100,000
– –
APTV icon
47
Aptiv
APTV
$12.4B
$10.3M 0.42%
150,000
– –
NKTR icon
48
CALL
Nektar Therapeutics
NKTR
$2.31B
$10.3M 0.41%
53,333
+33,333
+167% +$5.9M
CTSH icon
49
CALL
Cognizant
CTSH
$26.3B
$9.78M 0.4%
+200,000
New +$9.75M
ZTS icon
50
CALL
Zoetis
ZTS
$33B
$9.68M 0.39%
300,000
– –
1
2
3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q2 2014 Portfolio in Review

As of Q2 2014, Artal Group held 110 positions worth $2.47B, down 10% from $2.76B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Artal Group withdrew a net $262M in Q2 2014, closing 25 positions and reducing 10 holdings. Its most notable exit was FURIEX PHARMACEUTICALS INC COM STK (DE), an estimated $78.4M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 25% of assets, up from 23% a quarter earlier, followed by Healthcare and Financials.

Against the trend, Artal Group opened a new position in Amazon worth $16.2M.

  • Artal Group's largest Q2 2014 buy was Amazon: 1,000,000 shares worth $16.2M.
  • Artal Group added most to AUXILIUM PHARAMCEUTICALS INC in Q2 2014, an estimated $14.7M increase.
  • Artal Group's biggest Q2 2014 reduction was Ralph Lauren, cutting an estimated $3.85M.
  • Artal Group fully exited FURIEX PHARMACEUTICALS INC COM STK (DE) in Q2 2014, selling an estimated $78.4M.
  • Artal Group's ten largest holdings make up 61% of its $2.47B portfolio in Q2 2014.
  • Artal Group opened 16 new positions and closed 25 in Q2 2014.
  • Artal Group's portfolio value fell 10% quarter-over-quarter to $2.47B.

Based on Artal Group's 13F filing for Q2 2014, filed 14 Aug 2014.